Eugene Wyatt to Animals
This is a "connection" page, showing publications Eugene Wyatt has written about Animals.
Connection Strength
0.146
-
Mutation-Based Therapy for Duchenne Muscular Dystrophy: Antisense Treatment Arrives in the Clinic. Circulation. 2017 09 12; 136(11):979-981.
Score: 0.034
-
Welcome to the splice age: antisense oligonucleotide-mediated exon skipping gains wider applicability. J Clin Invest. 2016 Apr 01; 126(4):1236-8.
Score: 0.031
-
Regulation and cytoprotective role of hexokinase III. PLoS One. 2010 Nov 03; 5(11):e13823.
Score: 0.021
-
JUN Regulation of Injury-Induced Enhancers in Schwann Cells. J Neurosci. 2022 08 24; 42(34):6506-6517.
Score: 0.012
-
A role for alternative splicing in circadian control of exocytosis and glucose homeostasis. Genes Dev. 2020 08 01; 34(15-16):1089-1105.
Score: 0.010
-
Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies. Front Immunol. 2020; 11:1185.
Score: 0.010
-
A gene-edited mouse model of limb-girdle muscular dystrophy 2C for testing exon skipping. Dis Model Mech. 2019 11 04; 13(2).
Score: 0.010
-
Reengineering a transmembrane protein to treat muscular dystrophy using exon skipping. J Clin Invest. 2015 Nov 02; 125(11):4186-95.
Score: 0.007
-
Hexokinase II knockdown results in exaggerated cardiac hypertrophy via increased ROS production. EMBO Mol Med. 2012 Jul; 4(7):633-46.
Score: 0.006
-
Reduction in hexokinase II levels results in decreased cardiac function and altered remodeling after ischemia/reperfusion injury. Circ Res. 2011 Jan 07; 108(1):60-9.
Score: 0.005